Apremilast-d<sub>5</sub>

Apremilast-d5

CAT N°: 22553
Price:

From 276.00 234.60

Apremilast-d5 is intended for use as an internal standard for the quantification of apremilast (Item No. 18502) by GC- or LC-MS. Apremilast is an inhibitor of phosphodiesterase 4 (PDE4) with an IC50 value of 74 nM when tested in U937 cell lysates with 1 mM cAMP.{29958,29960} It is orally active, significantly decreasing epidermal thickness and the epithelial cell proliferation index in a mouse model of psoriasis.{29960} Apremilast reduces both TNF-? and matrix metalloproteinase-3 production in gut lamina propria mononuclear cells from patients with inflammatory bowel disease.{29957} It also blocks spontaneous production of TNF-? from human rheumatoid synovial cells and improves the clinical score in mouse models of arthritis.{29959}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[2-[(1S)-1-[3-(ethoxy-1,1,2,2,2-d5)-4-methoxyphenyl]-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-acetamide
  • Correlated keywords
    • deuterated deuterium gases chromatography isotope GC/MS LC-MS LC/MS GCMS LCMS PDE-4 CC-10004 CC10004 cyclic TNFa MMP3 MMP-3
  • Product Overview:
    Apremilast-d5 is intended for use as an internal standard for the quantification of apremilast (Item No. 18502) by GC- or LC-MS. Apremilast is an inhibitor of phosphodiesterase 4 (PDE4) with an IC50 value of 74 nM when tested in U937 cell lysates with 1 mM cAMP.{29958,29960} It is orally active, significantly decreasing epidermal thickness and the epithelial cell proliferation index in a mouse model of psoriasis.{29960} Apremilast reduces both TNF-? and matrix metalloproteinase-3 production in gut lamina propria mononuclear cells from patients with inflammatory bowel disease.{29957} It also blocks spontaneous production of TNF-? from human rheumatoid synovial cells and improves the clinical score in mouse models of arthritis.{29959}

We also advise you